GSK has claimed approval in the EU for Exdensur, a long-acting respiratory drug that is considered one of its top growth prospects. The approval of Exdensur (depemokimab) for severe asthma and chronic ...
ConsumerAffairs is not a government agency. Companies displayed may pay us to be Authorized or when you click a link, call a number or fill a form on our site. Our content is intended to be used for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results